Vistagen Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
VTGN Nasdaq 2830 www.vistagen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vistagen Therapeutics, Inc.

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - Jun 15th, 2026 2:30 pm
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder - Jun 9th, 2026 6:30 am
HealthEquity (HQY) Q1 Earnings and Revenues Top Estimates - May 28th, 2026 3:40 pm
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference - May 27th, 2026 6:30 am
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates - May 20th, 2026 6:15 am
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer - May 19th, 2026 6:30 am
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results? - May 19th, 2026 5:08 am
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates - May 18th, 2026 7:00 am
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - May 14th, 2026 6:30 am
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - May 12th, 2026 5:30 am
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder - May 8th, 2026 5:30 am
Vistagen Receives FDA "Study May Proceed" Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause - Apr 22nd, 2026 6:30 am
Vistagen to Participate in Upcoming Investor Conferences - Mar 3rd, 2026 6:30 am
Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference - Feb 25th, 2026 6:30 am
VistaGen Therapeutics, Inc. Q3 2026 Earnings Call Summary - Feb 13th, 2026 6:30 am
Vistagen Therapeutics Inc (VTGN) Q3 2026 Earnings Call Highlights: Progress in Clinical Trials ... - Feb 12th, 2026 10:02 pm
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates - Feb 12th, 2026 3:45 pm
Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update - Feb 12th, 2026 2:30 pm
Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026 - Feb 4th, 2026 6:30 am
US Equity Markets Fall as Technology Stocks Slump Amid Oracle Concerns - Dec 17th, 2025 2:22 pm